What are the differences between Hepatitis A (HA), Hepatitis B (HB), and Hepatitis C (HC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hepatitis A, B, and C are distinct viral infections affecting the liver, but they differ in transmission, prevention, and long-term outcomes, with Hepatitis C being the most severe in terms of chronic infection and liver damage risk. The main differences between Hepatitis A, B, and C are:

  • Transmission: Hepatitis A is typically transmitted through contaminated food or water, Hepatitis B through blood, semen, and other body fluids, and Hepatitis C primarily through blood contact.
  • Chronic infection risk: Hepatitis A does not become chronic, Hepatitis B has a 5-10% chronic infection risk in adults, and Hepatitis C has a 75-85% chronic infection risk.
  • Prevention: Vaccines exist for Hepatitis A and B, but not for Hepatitis C.
  • Treatment: Hepatitis A typically requires supportive care, chronic Hepatitis B may be treated with antiviral medications like entecavir or tenofovir, and Hepatitis C is highly curable with direct-acting antivirals such as sofosbuvir/velpatasvir (Epclusa) or glecaprevir/pibrentasvir (Mavyret) 1. Some key statistics and recommendations include:
  • Hepatitis B affects an estimated 257 million people worldwide and resulted in 887,000 deaths in 2015 alone 1.
  • Hepatitis C infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide 1.
  • The use of HBV vaccines has resulted in a reduction of chronically infected children under the age of five from 4.7% in the prevaccination era to 1.3% 1.
  • Antiviral treatment for chronic Hepatitis B may be recommended for patients with serum HBV DNA level > 20,000 IU/mL and serum ALT level > 2 ULN 1.
  • Direct-acting antivirals for Hepatitis C have achieved cure rates above 95% 1. In terms of management, it is crucial to prioritize the treatment of chronic Hepatitis C due to its high risk of liver damage and cancer, and to consider antiviral treatment for chronic Hepatitis B based on serum HBV DNA and ALT levels.

From the Research

Hepatitis A, B, and C: Key Differences

  • Hepatitis A, B, and C are viral infections that affect the liver, but they have distinct differences in terms of transmission, symptoms, and treatment options.
  • Hepatitis A is typically spread through contaminated food or water, while hepatitis B and C are usually transmitted through blood or bodily fluids 2.
  • Hepatitis B and C can lead to chronic infections, which increase the risk of liver cirrhosis and hepatocellular carcinoma (HCC) 3, 4, 5.

Risk of Hepatocellular Carcinoma (HCC)

  • The risk of HCC is significantly higher in individuals with chronic hepatitis B and C infections, particularly those with HBV-HCV coinfection 3.
  • The pooled analysis of 63 studies showed that the risk of HCC was significantly higher in individuals positive for HBsAg, HBV DNA or HBeAg, and HBV and HCV coinfection 3.
  • Hepatitis B virus infection can promote HCC development without prior end-stage liver disease 4.

Treatment and Prevention

  • Effective prevention and management strategies for HBV infection are crucial in reducing liver-related complications, including HCC 6.
  • New diagnostics and highly effective, pangenotypic direct-acting antivirals provide opportunities to cure and eradicate chronic hepatitis C virus infection 2.
  • Understanding the role of hepatitis B and C viral infections in HCC development is essential for the future design of treatments and therapies for this cancer 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Viral hepatitis and liver cancer.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.